Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Front Immunol ; 12: 791780, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-35046950

RESUMEN

Objective: We aimed to investigate the associations between the intestinal microbiota, metabolites, cytokines, and clinical severity in anti-N-methyl-d-aspartate receptor (NMDAR) encephalitis and to further determine the predictive value of the intestinal microbiota or metabolites in clinical prognosis. Methods: In this prospective observational cohort study of 58 NMDAR encephalitis patients and 49 healthy controls, fecal microbiota, metabolites, and cytokines were quantified and characterized by16S rRNA gene sequencing, liquid chromatography-mass spectrometry, and the Luminex assay, respectively. Results: There were marked variations in the gut microbiota composition and metabolites in critically ill patients. We identified 8 metabolite modules (mainly characterized by fatty acid, glycerophosphoethanolamines, and glycerophosphocholines) that were distinctly classified as negatively or positively associated with bacterial co-abundance groups (CAGs). These CAGs were mainly composed of Bacteroides, Eubacterium_hallii_group, Anaerostipes, Ruminococcus, Butyricicoccus, and Faecalibacterium, which were substantially altered in patients. In addition, these fecal and serum metabolic modules were further correlated with the serum cytokines. Additionally, the combination of clinical features, microbial marker (Granulicatella), and a panel of metabolic markers could further enhance the performance of prognosis discrimination significantly, which yielded an area under the receiver operating characteristic curve of (AUC) of 0.94 (95%CI = 0.7-0.9). Patients with low bacterial diversity are more likely to develop relapse than those with higher bacterial diversity (log-rank p = 0.04, HR = 2.7, 95%CI = 1.0-7.0). Interpretation: The associations between the multi-omics data suggested that certain bacteria might affect the pathogenesis of NMDAR encephalitis by modulating the metabolic pathways of the host and affecting the production of pro-inflammatory cytokines. Furthermore, the disturbance of fecal bacteria may predict the long-term outcome and relapse in NMDAR encephalitis.


Asunto(s)
Encefalitis Antirreceptor N-Metil-D-Aspartato/inmunología , Encefalitis Antirreceptor N-Metil-D-Aspartato/metabolismo , Encefalitis Antirreceptor N-Metil-D-Aspartato/microbiología , Eje Cerebro-Intestino/fisiología , Microbioma Gastrointestinal/fisiología , Adulto , Estudios de Casos y Controles , Femenino , Humanos , Masculino , Pronóstico , Estudios Prospectivos , Índice de Severidad de la Enfermedad
2.
Artículo en Inglés | MEDLINE | ID: mdl-31624178

RESUMEN

OBJECTIVE: To determine whether the gut microbiota shows overabundance of commensal bacteria species in patients with anti-NMDA receptor (NMDAR) encephalitis, similar to patients with MS or neuromyelitis optica where they potentially balance pro- and anti-inflammatory immune responses or participate in disease pathogenesis by molecular mimicry. METHODS: Intestinal microbiota was characterized in patients with NMDAR encephalitis (n = 23, mean age: 34 ± 12.7 years; 21 females) and age/sex/environment-matched healthy controls (n = 24, 40 ± 14.2 years; 22 females) using stool bacteria 16S rDNA sequencing and classification in operational taxonomic units (OTUs). Statistical analyses focused on intraindividual and interindividual bacterial diversity and identification of differentially abundant taxa. RESULTS: Patients with NMDAR encephalitis and controls had similar microbiome profiles of the gut microbiota regarding intraindividual bacterial diversity, OTU distribution, ratio between regional and local species diversity when testing all OTUs, and genera with a relative abundance greater than 0.5%. Similarly, the subgroup of NMDAR encephalitis patients with an ovarian teratoma (n = 3) showed no differences in microbiome variation compared with controls. Patients in the acute encephalitis stage (n = 8) showed significant differences in the numbers of Clostridium XVIII, Clostridium IV, Oscillibacter, Prevotella, and Blautia; however, significance was lost after correction for multiple testing. CONCLUSION: Patients with NMDAR encephalitis and controls both had a normal gut microbiome. The lack of overabundance of certain bacterial species in patients suggests that microbiome changes are no major contributors to the pathogenesis, disease course, or prognosis in NMDAR encephalitis. Despite the small sample size and heterogeneous groups, findings indicate differences to other neuroimmunologic diseases.


Asunto(s)
Encefalitis Antirreceptor N-Metil-D-Aspartato/microbiología , Microbioma Gastrointestinal , Enfermedad Aguda , Adulto , Heces/microbiología , Femenino , Humanos , Masculino , Persona de Mediana Edad
3.
Ann Clin Transl Neurol ; 6(9): 1771-1781, 2019 09.
Artículo en Inglés | MEDLINE | ID: mdl-31448571

RESUMEN

OBJECTIVE: To explore the diversity and composition of the fecal microbiota in patients with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. METHODS: We enrolled 10 patients in the acute stage with naïve treatment, seven patients with relapse, 13 patients without relapse in the remission phase, and 12 paired healthy controls. The fecal microbiota in different groups was compared by 16S ribosomal DNA (rDNA) gene pyrosequencing. RESULTS: Prominent dysbiosis in the gut microbiome of patients with anti-NMDAR encephalitis was found. Our primary findings showed that the overall species richness (alpha diversity indexes) of the microbiota was higher in patients than in controls (P < 0.05). Distance-based community analysis revealed that the microbiota differed substantially within all subgroups of patients and controls (P < 0.05). The relative abundance of species heatmap showed a tendency toward depletion for some commensal genera, such as Prevotella_6, Bifidobacterium, Faecalibacterium, and other short-chain fatty acid (SCFA)-producing bacteria. Additionally, our results showed that all subgroups had a distinct bacterial species, with an increase in the genus Fusobacterium in the acute phase group and the genera Streptococcus and Parabacteroides in patients with relapse. However, the genus Bacteroides was very abundant in patients without relapse. Although the findings regarding the Firmicutes/Bacteroidetes (F/B) ratios across the four comparison groups were not statistically significant, the F/B ratio gradually increased in patients from the acute phase group (0.87), to the disease remission group with relapse (1.06), to the group without relapse (1.28), to the healthy group (1.63). INTERPRETATION: Patients with anti-NMDAR encephalitis exhibit a substantial alteration in fecal microbiota composition.


Asunto(s)
Encefalitis Antirreceptor N-Metil-D-Aspartato/microbiología , Disbiosis/microbiología , Microbioma Gastrointestinal/fisiología , Adolescente , Adulto , Heces/microbiología , Femenino , Humanos , Masculino , Persona de Mediana Edad , ARN Ribosómico 16S , Adulto Joven
4.
Dev Med Child Neurol ; 59(8): 796-805, 2017 08.
Artículo en Inglés | MEDLINE | ID: mdl-28439890

RESUMEN

AIM: To conduct a systematic literature review on patients with biphasic disease with herpes simplex virus (HSV) encephalitis followed by anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. METHOD: We conducted a case report and systematic literature review (up to 10 December 2016), focused on differences between herpes simplex encephalitis (HSE) and anti-NMDAR encephalitis phases, age-related characteristics of HSV-induced anti-NMDAR encephalitis, and therapy. For statistical analyses, McNemar's test, Fisher's test, and Wilcoxon rank sum test were used (two-tailed significance level set at 5%). RESULTS: Forty-three patients with biphasic disease were identified (31 children). Latency between HSE and anti-NMDAR encephalitis was significantly shorter in children than adults (median 24 vs 40.5d; p=0.006). Compared with HSE, anti-NMDAR encephalitis was characterized by significantly higher frequency of movement disorder (2.5% vs 75% respectively; p<0.001), and significantly lower rate of seizures (70% vs 30% respectively; p=0.001). Compared with adults, during anti-NMDAR encephalitis children had significantly more movement disorders (86.7% children vs 40% adults; p=0.006), fewer psychiatric symptoms (41.9% children vs 90.0% adults; p=0.025), and a slightly higher median modified Rankin Scale score (5 in children vs 4 in adults; p=0.015). During anti-NMDAR encephalitis, 84.6 per cent of patients received aciclovir (for ≤7d in 22.7%; long-term antivirals in 18.0% only), and 92.7 per cent immune therapy, but none had recurrence of HSE clinically or using cerebrospinal fluid HSV polymerase chain reaction (median follow-up 7mo). INTERPRETATION: Our review suggests that movement disorder may help differentiate clinically an episode of HSV-induced anti-NMDAR encephalitis from HSE relapse. Compared with adults, children have shorter latency between HSE and anti-NMDAR encephalitis and, during anti-NMDAR encephalitis, more movement disorder, fewer psychiatric symptoms, and slightly more severe disease. According to our results, immune therapy given for HSV-induced anti-NMDAR encephalitis does not predispose patients to HSE recurrence.


Asunto(s)
Encefalitis Antirreceptor N-Metil-D-Aspartato/fisiopatología , Encefalitis por Herpes Simple/fisiopatología , Trastornos Mentales/fisiopatología , Trastornos del Movimiento/fisiopatología , Simplexvirus/patogenicidad , Adulto , Encefalitis Antirreceptor N-Metil-D-Aspartato/complicaciones , Encefalitis Antirreceptor N-Metil-D-Aspartato/etiología , Encefalitis Antirreceptor N-Metil-D-Aspartato/microbiología , Niño , Encefalitis por Herpes Simple/complicaciones , Femenino , Humanos , Trastornos Mentales/etiología , Trastornos del Movimiento/etiología
5.
Pediatr Infect Dis J ; 35(7): 816-7, 2016 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-27093160

RESUMEN

Anti-N-methyl-D-aspartate receptor encephalitis is a neuroimmunologic disorder that has been increasingly diagnosed during the past 5 years. It provokes a predictable syndrome treated with several immunomodulatory agents, such as corticosteroids and/or biologics. We managed a child with this disease who developed Pneumocystis jirovecii pneumonia as a direct infectious complication of the use of rituximab.


Asunto(s)
Encefalitis Antirreceptor N-Metil-D-Aspartato/tratamiento farmacológico , Encefalitis Antirreceptor N-Metil-D-Aspartato/microbiología , Pneumocystis carinii/aislamiento & purificación , Neumonía por Pneumocystis/tratamiento farmacológico , Neumonía por Pneumocystis/patología , Encefalitis Antirreceptor N-Metil-D-Aspartato/patología , Encefalitis Antirreceptor N-Metil-D-Aspartato/virología , Productos Biológicos/efectos adversos , Productos Biológicos/uso terapéutico , Humanos , Factores Inmunológicos/uso terapéutico , Lactante , Masculino , Rituximab/efectos adversos , Rituximab/uso terapéutico
6.
Pediatr Infect Dis J ; 33(8): 882-3, 2014 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-25222311

RESUMEN

We report the case of a boy with an encephalopathy associated with extrapyramidal and psychiatric symptoms and anti-N-methyl-D-aspartate receptor antibodies. He had positive serum antithyroid antibodies, IgM antibodies against Mycoplasma pneumoniae and human herpesvirus 7 polymerase chain reaction in the cerebrospinal fluid. He was successfully treated with rituximab, after steroids, intravenous immunoglobulin and plasma exchange. The pathophysiology of this disorder may be post-infectious and autoimmune.


Asunto(s)
Encefalitis Antirreceptor N-Metil-D-Aspartato/microbiología , Anticuerpos Antibacterianos/líquido cefalorraquídeo , Anticuerpos Antivirales/líquido cefalorraquídeo , Autoanticuerpos/sangre , Herpesvirus Humano 7/inmunología , Inmunoglobulina M/líquido cefalorraquídeo , Mycoplasma pneumoniae/inmunología , Encefalitis Antirreceptor N-Metil-D-Aspartato/tratamiento farmacológico , Encefalitis Antirreceptor N-Metil-D-Aspartato/inmunología , Encefalitis Antirreceptor N-Metil-D-Aspartato/virología , Anticuerpos Monoclonales de Origen Murino/uso terapéutico , Niño , Humanos , Factores Inmunológicos/uso terapéutico , Masculino , Rituximab
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA